Ophthalmic Drugs Market Forecast 2014-2024

LONDON, June 18, 2014 /PRNewswire/ --

Prospects for Leading Companies 

Ophthalmic drugs - new study showing you trends, R&D progress, and predicted revenues
Where is the ophthalmic drugs market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 337-page report provides 198 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of ten exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Cathy Yelf, Head of External Relations, Macular Society
• RNIB (Royal National Institute of Blind People)
• Charles C Wykoff, Dr, Retina Consultants of Houston
• Manju Subramanian, Associate Professor, Boston University School of Medicine
• Vanda Pharmaceuticals
• Professor David T. Shima, PhD, Institute of Ophthalmology, University College London
• Anonymous interview
• Sean Ainsworth, CEO and Founder of RetroSense Therapeutics
• Philip G. Ralston, Jr., CEO of MacuCLEAR
• Dr Michael Stewart, Associate Professor, Mayo Clinic

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for these five submarkets:
• Retinal disorders
• Allergic, inflammatory and infective drugs
• Glaucoma
• Dry eye
• Other treatments.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

See revenue forecasts for products
How will leading drugs perform to 2024 at world level? Our study forecasts sales of 26 products, including these brands:
• Lucentis
• Eylea
• Restasis
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Refresh brand products
• Pataday
• Vigamox

Discover how high revenues can go. You see what's happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 leading national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• Mexico
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that India, China, Mexico and Brazil, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth
Overall world revenue for ophthalmic drugs will reach $20.9bn in 2014, our work forecasts. We predict steady revenue growth from 2014 to 2024. Rising demand for ophthalmic drugs, expanding healthcare coverage, the strength of the R&D pipeline and developments in drug delivery technologies will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
• Novartis (Alcon)
• Allergan
• Roche
• Valeant (including Bausch & Lomb)
• Regeneron
• Santen
• Pfizer
• Merck & Co.
• Bayer
• Senju

A company profile gives you the following information:
• Revenue forecast for ophthalmic drugs from 2014 to 2024
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? You see trends for these areas:
• Retinal disorders
• Allergic, inflammatory and infective drugs
• Glaucoma
• Dry eye
• Other progress in ophthalmology.

Our study also discusses these agents and technologies, among others:
• Drug delivery
• Oral drug candidates
• Novel small molecules
• Gene therapy.

Ophthalmology holds strong, promising R&D. Novel compounds and new formulations with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.

What issues will affect the ophthalmic drugs industry?
Our new report discusses issues and events affecting the ophthalmic drugs market. You will find discussions, including qualitative analyses:
• Increasing demand for ophthalmic drugs due to demographic trends
• A strong R&D pipeline
• Patent expiry and generic competition
• Growth areas such as wet AMD and dry eye
• Advances in topical drug delivery
• Sustained-release ocular implants
• Pricing and reimbursement issues

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies report helps you
In summary, our 337-page report gives you the following knowledge:
• Revenues forecast to 2024 for the world ophthalmic drugs market and 5 product categories (therapeutic classes) - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2024 for the leading 12 national markets - US, Japan, China, Germany, France, UK, Italy, Spain, India, Brazil, Russia, Mexico and Rest of the World
• Assessment of 10 leading companies - hear about products, results and strategies including revenue forecasts for ophthalmic drugs to 2024
• Predicted revenues of 26 leading ophthalmic drugs to 2024 - see potentials of top products
• Review of R&D pipelines - investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with ten leading authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at            sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1279/Ophthalmic-Drugs-Market-Forecast-2014-2024

Companies Listed in this report: 

Abbott Laboratories (Abbott)
Abbvie
Actavis
Acucela
Advanced Cell Technologies
Aerie Pharmaceuticals
Aerpio Therapeutics
Akorn Pharmaceuticals
Alcon (subsidiary of Novartis)
Aldeyra Therapeutics
Alembic
Alimera Sciences
Allergan
Allergro Ophthalmics
Amakem
Amgen
Ampio Pharmaceuticals
Apotex
Asahi Glass
AstraZeneca
Aton Pharma (acquired by Valeant)
Banyu Pharmaceutical (part of Merck)
Barr Laboratories (subsidiary of Teva)
Bausch and Lomb (B&L) (acquired by Valeant)
Bayer
Bicycle Therapeutics
Biocad
BioDiem
Biovail Corporation (part of Valeant)
Bristol-Myers Squibb
Can-Fite BioPharma
Chengdu Kanghong Pharmaceutical
Chiron Corporation (part of Novartis)
Chugai Pharmaceutical (part of Roche)
CIBA VISION (part of Novartis)
Ciba-Geigy (part of Novartis)
Cipla
Clinical Specialties
Colby Pharmaceutical Company (Colby)
Compañía Internacional de Comercio, S.A.P.I. de C.V. (CISCA) (acquired by Taisho)
Daiichi Sankyo
Delenex Therapeutics
Eleven Biotherapeutics
Eli Lilly and Company (Lilly)
ESBATech (part of Novartis)
EyeCyte
EyeGate Pharmaceuticals
Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)
ForeSight Biotherapeutics
ForSight VISION4 / ForSight Labs
Fougera Pharmaceuticals (acquired by Novartis)
Fujifilm Kyowa Kirin Biologics
Genaera Corporation
Gene Signal
Genentech (subsidiary of Roche)
Genzyme (subsidiary of Sanofi)
Grupo Imperial (acquired by Taisho)
GSK
High-Tech Pharmacal
ICN Pharmaceuticals (original Valeant company)
iCo Therapeutics
Icon Bioscience
Inamed Corporation (subsidiary of Allergan)
InSite Vision
Inspire Pharmaceuticals (acquired by Merck)
Instituto Terapeutico Delta Ltda (acquired by Valeant)
ISTA Pharmaceuticals (part of Valeant)
Jenapharm (part of Bayer)
Jerini Ophthalmic (acquired by Shire)
Johnson & Johnson (J&J)
Kala Pharmaceuticals
KalVista
Kestrel Ophthalmics
Kosei (acquired by Taisho)
Kyorin Pharmaceutical
Kyowa Hakko Kirin
Laboratorios Grin (acquired by Lupin)
Laboratorios Kendrick (acquired by Sanofi)
LEO Pharma
Lpath
Lupin Limited
MacuCLEAR
MacuSIGHT, Inc.
MAP Pharmaceuticals (acquired by Allergan)
Meda
Medicis Corporation (acquired by Valeant)
Merck & Co.
Merck KGaA
MerLion Pharmaceuticals
Mimetogen Pharmaceuticals
Molecular Partners AG
Morgan Stanley
MSD K.K. (part of Merck)
Mylan Pharmaceuticals
Mystic Pharmaceuticals
Nestlé
Neurim Pharmaceuticals
Neurotech
Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)
NovaBay Pharmaceuticals
Novagali Pharma (acquired by Santen)
Novartis
Novo (subsidiary of Novo Nordisk)
Novo Nordisk
Oakwood Laboratories
OcuSciences
OHR Pharmaceutical
Omeros
Oncobiologics
OphthaliX (part-owned by Can-Fite BioPharma)
Ophthotech
OPKO Health
Ora
Othera Pharmaceuticals (acquired by Colby)
Oxford BioMedica
OXiGENE / Symphony VIDA
PanOptica
Par Pharmaceutical
Parke-Davis (subsidiary of Pfizer)
Patheon Pharmaceuticals
Pershing Square Capital
Pfizer
Pharmacia (acquired by Pfizer)
Premacure (acquired by Shire)
Procter & Gamble (P&G)
pSivida
QLT
Quark Pharmaceuticals
Reckitt Benckiser
Regeneron
RetroSense Therapeutics
Roche
Roche Consumer Health (part of Bayer)
R-Tech Ueno
RXi Pharmaceuticals
Sandoz (division of Novartis)
Sanofi
Santen
SARcode Bioscience
Schering AG (part of Bayer)
Schering-Plough (part of Merck)
Seikagaku
Senju
Servier
Shire
Sirna Therapeutics
SkinMedica (subsidiary of Allergan)
Spark Therapeutics
Steigerwald (part of Bayer)
Sucampo Pharmaceuticals
Swedish Orphan Biovitrum (Sobi)
Symphony ViDA (acquired by OXiGENE)
Taisho
Takeda
Tecnofarma (acquired by Valeant)
Teva Pharmaceutical Industries (Teva)
The Patent Board
ThromboGenics
Upjohn (acquired by Pfizer through Pharmacia)
Valeant
Vanda Pharmaceuticals
Ventana Medical Systems (acquired by Roche)
Vitacilina Corporation of America (VitaCorp) (acquired by Taisho)
Warburg Pincus LLC
Warner-Lambert (acquired by Pfizer)
Watson Pharmaceuticals (now Actavis)
Wockhardt
Wyeth Pharmaceuticals (part of Pfizer)
Zhejiang Huahai Pharmaceutical
Zoetis

Other Organisations Mentioned in this Report
A*STAR Institute for Infocomm Research (Singapore)
American Academy of Ophthalmology (AAO)
American Diabetes Association
American Society of Retina Specialists (ASRS)
Association for Research in Vision and Ophthalmology (ARVO)
Bascom Palmer Eye Institute
Boston University Eye Associates/Boston Medical Center
Boston University School of Medicine
China Food and Drug Administration (CFDA)
Conseil d'Etat (France)
Department of Pharmaceuticals (India)
Emory University
European Commission
European Medicines Agency (EMA)
Foundation Fighting Blindness (FFB) (US)
Generic Pharmaceutical Association (GPhA) (US)
Harvard Medical School (US)
Health Canada
Institute of Experimental Medicine (Russia)
Institute of Ocular Pharmacology, Texas A&M (US)
Institute of Ophthalmology, University College London (UK)
International Diabetes Federation
Italian Competition Authority (ICA)
Japan Patent Office
Macular Society (UK)
Massachusetts Institute of Technology (MIT)
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Ministry of Health, Labour and Welfare (MHLW) (Japan)
Monash University
National Development and Reform Commission (NDRC) (China)
National Eye Institute (NEI) (US)
National Health Service (NHS) (UK)
National Institute for Health and Care Excellence (NICE) (UK)
National Pharmaceutical Pricing Authority (NPPA) (India)
NHS Scotland
Novartis Institutes for BioMedical Research (NIBR) (part of Novartis)
Ophthalmology External Research Unit (part of Pfizer)
Oxford University (UK)
Rashtriya Swasthya Bima Yojana (RSBY) (India)
Retina Consultants of Houston
Rinat (Pfizer research unit)
Royal National Institute of Blind People (RNIB) (UK)
Russian Ministry of Industry and Trade
Seguro Popular (Mexico)
Servicio Sanitario Nazionale (SSN) (Italy)
Sistema Único de Saúde (SUS) (Brazil)
Southampton, Hampshire, Isle of Wight and Portsmouth Primary Care Trust (UK)
Therapeutic Goods Administration (TGA) (Australia)
Tokyo University of Science
United Nations
United States Food and Drug Administration (FDA)
University College London (UCL)
University of Florida
University of Kentucky
University of Melbourne
University of Michigan
US Preventive Services Task Force (USPSTF)
US Securities and Exchange Commission (SEC)
World Bank
World Health Organization

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com